Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease

NCT04269642 is registered in ClinicalTrials.gov with Peptron, Inc. as lead sponsor.

NCT NCT04269642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04269642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease
Lead sponsor
Peptron, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
March 19, 2020
Completion date
December 31, 2021
Enrollment
99 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

early parkinson's disease